Merck & Company (DE:6MK)
XETRA:6MK
6MK Stock Chart & Stats
€102.08
€0.40(0.41%)
At close: 4:00 PM EST
€102.08
€0.40(0.41%)
Day’s Range― - ―
52-Week Range€65.50 - €105.70
Previous CloseN/A
Volume75.00
Average Volume (3M)2.08K
Market Cap
€255.27B
Enterprise Value€333.03B
Total Cash (Recent Filing)€14.56B
Total Debt (Recent Filing)€50.53B
Price to Earnings (P/E)14.5
Beta0.59
Next Earnings
Apr 30, 2026EPS Estimate
-1.26Next Dividend Ex-DateN/A
Dividend Yield3.18%
Share Statistics
EPS (TTM)1.73
Shares Outstanding2,472,392,000
10 Day Avg. Volume1,087
30 Day Avg. Volume2,076
Financial Highlights & Ratios
PEG Ratio1.88
Price to Book (P/B)5.02
Price to Sales (P/S)4.06
P/FCF Ratio21.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€113.94Price Target Upside11.62% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering20
EPS Forecast (FY)4.36
Revenue Forecast (FY)€56.90B
Bulls Say, Bears Say
Bulls Say
Acquisition Bolsters Oncology PipelineAcquisition of TERN brings a chronic myeloid leukemia asset with durable response data, lowering late‑stage development risk and strengthening Merck's oncology growth prospects.
HIV Franchise Expansion And DifferentiationMultiple late‑stage HIV programs aiming for less frequent oral dosing and a monthly prevention option could offer differentiated value to physicians and patients seeking reduced treatment burden.
Phase 2 Efficacy And SafetyCADENCE Phase 2 results met the primary pulmonary endpoint and showed a favorable safety profile with no increase in bleeding despite widespread anticoagulant use, supporting advancement to a registrational Phase 3 trial.
Bears Say
Dose‑response UncertaintyAn inverse dose response in CADENCE, where the higher dose underperformed the lower dose, raises questions about optimal dosing and could complicate Phase 3 planning and investor confidence.
Market Size And Competitive PressureLow diagnosis rates for the target condition combined with intense competition in HIV and oncology could limit patient uptake and constrain commercial potential even if clinical milestones are met.
Trial Interpretability ConcernsHeavy use of background heart failure therapies and anticoagulants in the study population complicates interpretation of efficacy signals, increasing uncertainty about how results will translate in broader practice.
Merck & Company News
6MK FAQ
What was Merck & Company’s price range in the past 12 months?
Merck & Company lowest stock price was €65.50 and its highest was €105.70 in the past 12 months.
What is Merck & Company’s market cap?
Merck & Company’s market cap is €255.27B.
When is Merck & Company’s upcoming earnings report date?
Merck & Company’s upcoming earnings report date is Apr 30, 2026 which is in 16 days.
How were Merck & Company’s earnings last quarter?
Merck & Company released its earnings results on Feb 03, 2026. The company reported €1.735 earnings per share for the quarter, beating the consensus estimate of €1.71 by €0.025.
Is Merck & Company overvalued?
According to Wall Street analysts Merck & Company’s price is currently Undervalued.
Does Merck & Company pay dividends?
Merck & Company pays a Quarterly dividend of €0.723 which represents an annual dividend yield of 3.18%. See more information on Merck & Company dividends here
What is Merck & Company’s EPS estimate?
Merck & Company’s EPS estimate is -1.26.
How many shares outstanding does Merck & Company have?
Merck & Company has 2,472,392,000 shares outstanding.
What happened to Merck & Company’s price movement after its last earnings report?
Merck & Company reported an EPS of €1.735 in its last earnings report, beating expectations of €1.71. Following the earnings report the stock price went up 3.259%.
Which hedge fund is a major shareholder of Merck & Company?
Currently, no hedge funds are holding shares in DE:6MK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Merck & Company Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€113.94 (11.62% Upside)
€113.94 (11.62% Upside)
Blogger Sentiment
Bullish
DE:6MK Sentiment 89%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $40.7M over
the Last 3 Months
the Last 3 Months
News Sentiment
Bullish
Bullish news 73%
Bearish news 27%
Bearish news 27%
Technicals
SMA
Positive
20 days / 200 days
Momentum
62.25%
12-Months-Change
Fundamentals
Return on Equity
36.19%
Trailing 12-Months
Asset Growth
16.87%
Trailing 12-Months
Company Description
Merck & Company
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
6MK Company Deck
6MK Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call balances near-term challenges (a sizable one-time Sidera acquisition charge, meaningful vaccine softness — notably Gardasil down 35% — RSV uptake below expectations, and an identified ~$2.5B headwind from generics and pricing reforms) against clear commercial and pipeline momentum (5% Q4 revenue growth, KEYTRUDA resilience, multiple high-growth product launches, strong specialty product performance, animal health growth, completed strategic acquisitions, and a materially expanded long‑term commercial opportunity with numerous near-term clinical readouts and regulatory milestones). While 2026 reported EPS and margins are being impacted by the acquisition charge and short-term pressures, management emphasizes durable long-term growth driven by a deep pipeline and new product launches, positioning the company for stronger growth beyond the LOE period.View all DE:6MK earnings summaries6MK Sales Breakdown
89.43% Pharmaceutical
9.77% Animal Health
0.79% Other
6MK Stock 12 Month Forecast
Average Price Target
€113.94
▲(11.62% Upside)
Technical Analysis
Options Prices
Currently, No data available
---